The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma
暂无分享，去创建一个
K. Muro | I. Oze | M. Tajika | K. Honda | W. Hosoda | H. Bando | M. Ando | S. Kadowaki | K. Nozawa | T. Masuishi | Y. Narita | T. Ogata | Y. Matsubara | T. Nakazawa | K. Kato | Kazuhiro Toriyama
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] Y. Bang,et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.
[3] G. Krigsfeld,et al. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types , 2020, Journal of Clinical Pathology.
[4] Y. Doki,et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) , 2014, Cancer science.
[5] H. Yamana,et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.